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Abstract
ErbB2+ human breast cancer is a major clinical problem. Prior results have suggested that tetraspanin CD151might
contribute to ErbB2-driven breast cancer growth, survival, and metastasis. In other cancer types, CD151 sometimes
supports tumor growth and metastasis. However, a definitive test of CD151 effects on de novo breast cancer ini-
tiation, growth, and metastasis has not previously been done. We used CD151 gene–deleted mice expressing the
MMTV-ErbB2 transgene to show that CD151 strongly supports ErbB2+ mammary tumor initiation and metastasis.
Delayed tumor onset (by 70-100 days) in the absence of CD151 was accompanied by reduced survival of mammary
epithelial cells and impaired activation of FAK- andMAPK-dependent pathways. Both primary tumors andmetastatic
nodules showed smooth, regular borders, consistent with a less invasive phenotype. Furthermore, consistent with
impaired oncogenesis and decreased metastasis, CD151-targeted MCF-10A/ErbB2 cells showed substantial
decreases in three-dimensional colony formation, EGF-stimulated tumor cell motility, invasion, and transendothelial
migration. These CD151-dependent functions were largely mediated through α6β4 integrin. Moreover, CD151
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ablation substantially prevented PKC- and EGFR/ERK–dependent α6β4 integrin phosphorylation, consistent with re-
tention of epithelial cell polarity and intermediate filament cytoskeletal connections, which helps to explain dimin-
ished metastasis. Finally, clinical data analyses revealed a strong correlation between CD151 and ErbB2 expression
and metastasis-free survival of breast cancer patients. In conclusion, we provide strong evidence that CD151 col-
laborates with LB integrins (particularly α6β4) and ErbB2 (and EGFR) receptors to regulate multiple signaling path-
ways, thereby driving mammary tumor onset, survival, and metastasis. Consequently, CD151 is a useful therapeutic
target in malignant ErbB2+ breast cancer.
Neoplasia (2012) 14, 678–689
Introduction
Epidermal growth factor receptor 2 (ErbB2/HER2), a member of the
epidermal growth factor receptor family, is amplified in 15% to 25% of
human breast cancers. This potent oncogenic receptor kinase drives
breast tumor development, progression, and metastasis, leading to
poor patient prognosis [1–3]. Despite advances in drug treatment of
ErbB2-amplified breast cancer (e.g., with trastuzumab, lapatinib),
many patients fail to respond or respond initially but become resis-
tant within 1 year [4]. Hence, the malignancy of ErbB2+ breast cancer
remains a significant clinical threat, and more treatment options
are needed.
Extensive studies from our group and others have shown that
CD151, a member of the tetraspanin protein family [5], contributes
to the malignancy of human cancer [6–9]. Analyses of human breast
tumor tissues have revealed significant elevation of CD151 expression
in human estrogen receptor–negative (ER−) tumors, which include
basal-like and ErbB2+ subtypes [10,11]. Further supporting clinical
relevance is the marked impact of CD151 onmammary tumor growth
and metastasis in xenograft studies using immunodeficient mice
[8,10]. Also, ablation of CD151 markedly impaired epidermal growth
factor (EGF)–mediated breast cancer cell attachment, motility, and
invasion; the cross-talk between integrins and ErbB receptors; and
tumor cell’s sensitivity to ErbB2 antagonists [12]. Together, these
results suggest that CD151 is a central player in the malignancy of
human ErbB2+ breast cancer and is a promising therapeutic target.
In both normal and malignant epithelial cells, CD151 is tightly
linked to cell surface adhesion receptors (α3β1, α6β1, α6β4), which
are the laminin binding (LB) integrins [10,13,14]. CD151 physically
interacts with LB integrin α3 or α6 subunit to form tight protein com-
plexes through their respective extracellular domains [13]. In addition,
CD151 orchestrates assembly of other tetraspanins and nontetraspanin
components into large complexes on the cell surface, known as
tetraspanin-enriched membrane microdomains (TEMs) [13]. There-
fore, it is postulated that CD151 affects LB integrin functions and
diverse cellular processes by modulating the lateral movement of these
adhesion molecules and by recruiting diverse signaling molecules,
including protein kinase C (PKC), into TEMs [10,13,15].
Despite more than 50 studies linking CD151 to various aspects of
tumor and tumor cell behavior, two critical results have been lacking: 1)
CD151 had not been shown to affect breast cancer initiation in a spon-
taneous (i.e., de novo) model and 2) the effects of CD151 on sponta-
neous tumor metastasis had not been analyzed. Given that CD151
functions through LB integrins (e.g., α3β1 and α6β4), which frequently
coexist on normal and malignant epithelial cells [7], but have poten-
tially opposing roles during tumor progression andmetastasis [16–19],
one cannot predict in advance how CD151 will affect tumor initiation
and metastasis.
To address definitively the roles of CD151 during in vivo tumor
onset, growth, and metastasis, we use CD151 wild-type and knockout
mice [20], combined with a spontaneous breast cancer mouse mam-
mary tumor virus (MMTV)–c-Neu (ErbB2) tumormodel [21]. Also, to
gain mechanistic insight into tumor cell autonomous roles of CD151
(i.e., free of tumor-stroma complications), we carried out extensive
in vitro functional and signaling analyses using three-dimensional cul-
tured mammary epithelial cells as a model. Our results demonstrate
that CD151 drives the onset and metastasis of ErbB2-evoked mam-
mary tumors. Loss of CD151 markedly impaired tumor cell survival
and activation of focal adhesion kinase (FAK)– andMAP kinase kinase
(MEK)/extracellular signal–regulated kinase (ERK)–mediated signal-
ing. These actions of CD151 are associated with integrin α3β1- and
α6β4-dependent cell attachment, motility, invasion, survival, and sig-
naling crosstalk with epidermal growth factor receptor (EGFR) and
ErbB2 receptors. Overall, our studies provide the first in vivo evidence
that CD151, a major partner of LB integrins, is a critical regulator of
mammary tumor onset and metastasis, particularly in the context of
ErbB2-evoked breast cancer.
Materials and Methods
Mice and In Vivo Tumor Analyses
ErbB2 transgenic FVBmice, which express multiple copies of intact
rat c-Neu gene under MMTV promoter [22], were purchased from
the Jackson Laboratory (Bar Harbor, ME). These mice typically form
mammary tumors (in 4-10 months), and after 8 months, most mice
also show tumor metastasis to lungs [22]. CD151-null mice were gen-
erated in house [20]. To enhance oncogenic susceptibility, CD151-
null mice on 129SVE background were backcrossed onto the FVB
background three times before being bred to ErbB2-overexpressing
transgenic animals. To minimize the influence of a pathologic kidney
phenotype, which may be evident in more fully inbred FVB [23,24],
CD151-null mice were not backcrossed further onto the FVB back-
ground. After intercrossing between ErbB2-expressing CD151+/−
mice, the resulting mouse littermates were transgenic for ErbB2 but
varied in CD151 genotype: +/+ (WT) or +/− (Het) or −/− (KO). At-
trition was minimal (<1% mice lost per year) and was not affected by
CD151 genotype. All mice were housed under identical conditions,
and tumors were scored blind by multiple independent individuals.
Mice were independently genotyped at the beginning and end of ex-
periments and examined twice weekly for palpable mammary tumors,
and tumor sizes were measured using calipers.
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At the end of in vivo experiments, tumor tissues, lung, and kidney
were collected and stored at −80°C for biochemical analyses or fixed in
10% neutral formalin (Sigma-Aldrich, St Louis, MO) and subsequently
stored in 70% ethanol before being embedded into paraffin block for
subsequent hematoxylin and eosin and immunohistochemistry (IHC)
analyses. Whole-mount analysis of mammary gland development was
carried out essentially as described [25]. Briefly, inguinal mammary
glands were surgically removed and fixed and followed by staining with
Carmine solution for 1 to 2 days. The stained glands were imaged
under dissecting microscope with a digital camera.
Cell Lines and Culture
Immortalized human mammary epithelial cells, MCF-10A (from
ATCC, Manassas, VA) and MCF-10A/ErbB2 (provided by J. Brugge
at Harvard Medical School), were maintained in medium supplemented
in 5%horse serum, insulin, and EGF as previously described [10]. Three-
dimensional culture of MCF-10A/ErbB2 cells was carried out essentially
according to the protocol described by Debnath and Brugge [26]. In
brief, cells were plated onto Matrigel-coated eight-well glass-bottom
chamber slides at 5 × 104 per well in the presence of culture medium
supplemented with 2% Matrigel (BD Bioscience, San Jose, CA), along
with various inhibitors or stimulants. The cultured medium was replaced
every second day until formation of acinar-like colonies. Mouse tumor
cell lines were generated from tumor-bearing transgenic animals as de-
scribed [25]. All cell cultures were carried out at 37°C under 5% CO2.
Antibodies and Reagents
Antibodies to mouse integrins and tetraspanin proteins were
obtained from BD Biosciences (San Jose, CA) or R&D Systems
(Minneapolis, MN). Antibodies to human integrins and tetraspanins
were raised in-house [10,27]. 1A5, an anti–human CD151 monoclo-
nal antibody, was a gift from Dr Zijlstra, Vanderbilt University. Anti-
bodies to cleaved caspase 3 and to total and/or phosphorylated forms of
AKT, EGFR, ErbB2, ErbB3, PAK1, and ERK1/2 were obtained from
Cell Signaling Technology (Danvers, MA). Antibodies against nuclear
factor κB (NF-κB) and to total and/or phospho-FAK, Src, and
p130CAS were from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies recognizing phospho-serine residues in the β4 cytoplasmic
tail were described elsewhere [27,28]. Antibody for Ki-67 was ob-
tained from Thermo-Fisher Scientific (Waltham, MA). Doxorubicin
was obtained from Sigma-Aldrich. FAK inhibitor (TAE-266) was a gift
from Novartis (Boston, MA). Inhibitors of the MEK/ERK pathway
(U0126) and EGFR and ErbB2 (lapatinib) were obtained from LC
Laboratories (Woburn, MA).
In Vitro Cell Function Assays
Static cell adhesion assays were carried out as described [15,29].
Briefly, semiconfluent cells were rinsed three times in phosphate-
buffered saline and detached using dissociation buffer (Invitrogen,
Carlsbad, CA), labeled with fluorescent dye, and then plated on
laminin-coated 96-well plates at 3 × 104 per well. After 45 minutes,
nonadherent cells were removed, and percent cell attachment was
determined based on fluorescence quantitation. Cell invasion was car-
ried out using a Matrigel-coated Boyden chamber in the presence of
10 ng/ml of EGF. Tumor cells seeded at 1 × 105 per well were allowed
to invade for 17 to 20 hours before quantitation as described [10]. For
measurement of random cell motility, cells were seeded onto 24-well
plates at 1.5 × 104 per well, placed into an OKALAB incubator
(equipped with a heater and gas mixer), and maintained at 37°C and
5%CO2. Images were obtained with aNikon Automated Eclipse Ti-E
inverted microscope (Nikon Instruments, Inc, Melville, NY) at 20-
minute intervals for 12 hours, and cell movement distance was quan-
tified using Nikon NIS Elements Advanced Analysis Software (Nikon
Instruments, Inc). For assessing transendothelial cell migration, 5-μm
pore polycarbonate transwell inserts were placed in 24-well plates
(Costar,Milpitas, CA) that had been precoated with a layer ofMatrigel
(BD Biosciences). Then, human umbilical vein endothelial cells
(Lonza, Walkersville, MD) were grown to a confluent monolayer, and
dye-labeled epithelial cells were seeded at 2 × 105 per well and allowed to
migrate for 6 hours at 37°C. Motile cells were stained and quantified
using the Nuance multispectral imaging system (Caliper Life Sciences,
Hopkinton, MA). Colony formation by mammary epithelial cells
under three-dimensional culture was assayed as described [26]. Size
and quantities of acinar-like colonies were determined using Nikon
NIS-Elements Advanced Analysis Software.
Transfection, Flow Cytometry, Immunofluorescence,
and IHC Analyses
Stable knockdown of more than 90% of CD151 proteins in
MCF-10A and MCF-10A/ErbB2 cells was carried out as previously
described [10] and confirmed by flow cytometry orWestern blot anal-
ysis with anti-CD151 monoclonal antibodies (5C11 and 1A5). For re-
expression analyses, intact CD151 and an extracellular domainmutant
(lacking integrin association [30]) were introduced into cells by using
retroviral infection and selected with 100 μg/ml Zeocin (Invitrogen).
The expression of cell surface molecules was analyzed by flow cytome-
try or by immunofluorescence staining of live cells grown under three-
dimensional conditions and imaged under a confocal microscope. To
detect intracellular proteins, cells were fixed and then stained with anti-
bodies [10] and visualized under a confocal microscope. IHC analyses
were carried out as previously described [10]. After antigen retrieval,
tumor sections were consecutively stained with primary antibodies
and biotin-conjugated secondary antibodies, followed by incubation
with Avidin and detection (DAB kit; BD Biosciences).
Analyses of Signaling, Co-immunoprecipitation,
and Immunoblot Analysis
For signaling analyses, cells were seeded onto six-well plates at 2 ×
105 cells per well. After overnight starvation, cells were stimulated and
lysed in RIPA buffer [10,12] supplemented with 1 mM NaV3O4 and
protease inhibitor cocktail. For examination of CD151 association
with integrin proteins, mouse tumor cells were radiolabeled with
[3H]-palmitate, lysed in buffer containing 1% Brij-96, and then im-
munoprecipitated with the indicated monoclonal antibodies, and
radiographic detection was as previously described [29,31]. For tissue
analyses, frozen tumor tissues were weighed and homogenized in ice-
cold 1:5 (vol/vol) RIPA buffer. Protein concentrations were measured
using DC Protein Determination Kit (Bio-Rad, Hercules, CA). Equal
amounts of proteins were separated on SDS-PAGE, transferred onto
nitrocellulose membrane, and then blotted with the indicated anti-
bodies. For each set of samples shown, proteins have been run, blotted,
and examined on the same gel and the same membrane.
Analysis of Metastasis-Free Survival of Breast Cancer Patients
Single-gene (CD151 alone, ErbB2 alone) and two-gene (CD151
and ErbB2) signature-based analyses were conducted on multiple inde-
pendent human breast cancer data sets. The binary group assignments
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for each patient sample were determined on the basis of first bifurcation
of the clustering dendrograms [32].
Results
Disruption of CD151 Delays the Onset of ErbB2-Evoked
Mammary Tumors in Mice
To evaluate the contribution of CD151 to ErbB2-evoked mammary
tumorigenesis in vivo, mouse littermates expressing ErbB2 and vari-
ous CD151 genotypes were examined for initial tumor appearance
and growth over 420 days. As shown (Figure 1A), deletion of single
(CD151+/−) or both (CD151−/−) alleles led to a significant delay in
tumor onset (102 and 69 days, respectively). However, deletion of
CD151 seemed to minimally influence tumor growth rate monitored
during a 3-week interval (Figure 1B). Also, CD151 removal did not alter
the extent of tumor vascularization (data not shown). In addition, multi-
plicity of mammary tumors remained unaffected, with less than 5% of
the animals developing more than one tumor over the course of the
experiment (data not shown), as expected for mice expressing the intact
ErbB2/c-neu transgene [22]. Moreover, tumors from CD151+/+ mice
(Figure 1C) exhibited solid nodular structures, extensive stromal infil-
trates, and protruding borders [33]. In contrast, these morphologic fea-
tures were less apparent in most tumors derived from CD151−/− mice,
largely resembling those of noninvasive ductal carcinoma in situ [34].
CD151 Promotes Spontaneous Metastasis of ErbB2-Induced
Mammary Tumors
Next, we assessed the impact of CD151 deletion on spontaneous
pulmonary metastasis in ErbB2 transgenic mice. To exclude effects
of tumor burden, lungs were collected from mice only after primary
tumors had reached ∼4.2 cm3 in size. The number of metastatic le-
sions per lung in wild-type mice (∼7.5/lung) was significantly reduced
in CD151+/− (∼4/lung) and CD151−/− mice (∼2/lung) (Figure 2A).
Furthermore, the morphologies of metastatic lesions differed markedly
between these groups. Whereas lesions from CD151+/+ mice were
multifocal, nodular, and characterized by extensive stromal infiltra-
tion, those fromCD151−/−mice were more sheet-like and reminiscent
of morphologies seen in less invasive mammary tumors (Figure 2B).
With loss of CD151 alleles, there was also a trend toward reduced in-
cidence of pulmonary metastases (Figure W1A), and the average size
of metastatic lesions in CD151+/− and CD151−/− mice was 44% to
51% of that in CD151+/+ mice (Figure W1B).
Although CD151-het mice showed substantially delayed tumor
initiation and reduced metastasis, there was no evidence for kidney
Figure 1. Impact of CD151 removal on ErbB2-induced mammary
tumorigenesis. (A) Kaplan-Meier plots for tumor-free survival com-
paring mice with varying CD151 genotypes. The median time to
tumor onset (in days) is shown. (B) Tumor volume (mean±SEM) over
time, starting with initial tumor detection, is indicated for tumor-
bearing mice (for each group, n = 15). (C) Representative images of
hematoxylin and eosin–stained primary tumor sections prepared from
a total of 20 to 25 mice per CD151 genotype. Scale bar, 100 μm.
Figure 2. CD151 deletion and pulmonary metastasis. (A) Numbers
of pulmonary lesions permouse, plus average values, are indicated.
Differences were assessed using nonparametric Kruskal-Wallis test;
P values are indicated. Numbers of mice with pulmonary metastasis
are indicated for each CD151 genotype. (B) Typical hematoxylin and
eosin–stained sections of pulmonary lesions from wild-type and null
tumor-bearing mice. Scale bar, 100 μm.
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pathology in the 109 CD151-het mice analyzed. Among the 58 CD151-
null mice analyzed, none showed loss of body weight or any other
visual evidence for poor health, during nearly 2 years of monitoring.
However, on inspection of the kidneys, 3 of 58 mice did show
apparent kidney pathology (Figure W2) similar to that previously
described [23].
Impaired Tumor Onset in CD151-null Mice Is Associated
with Decreased Cell Survival and Signaling
To gain mechanistic insight into the role of CD151 in tumor onset,
proliferation and survival were analyzed. CD151 deletion caused little
change in the number of primary tumor cells positive for proliferation
marker Ki-67 (Figure 3A, left panels). In contrast, the number of
cleaved caspase 3–positive cells in CD151-deficient tumors was signif-
icantly increased compared with wild-type (P < .05; Figure 3, right
panels). Relative to total cells analyzed, the extent of survival decreased
6.0% (7.5% − 1.5%).
To understand mechanisms by which CD151 may support epithe-
lial cell survival, changes in ErbB2-mediated signaling pathways were
analyzed in four representative individual tumor samples derived from
each of CD151 wild-type and null groups. As indicated (Figure 4A),
there wasminimum consistent change in total or phosphorylated levels
of ErbB2, EGFR, or AKT in primary tumors, in agreement with our
prior studies of CD151 in human ER− breast cancer cells [10,12].
However, activation of ERK, a critical downstream effector of ErbB2
and integrin signaling, was markedly decreased when CD151 was de-
leted (Figure 4A, compare lanes 5-8 with lanes 1-4 ). Despite dimin-
ished activation of ERK, there was little change in activation of
p90RSK (a downstream effecter of ERK, which can mediate survival
[35,36]) or p38 MAPK (an alternate pathway to ERK; Figure 4A).
Activation of FAK, a pivotal downstream effector of integrin signal-
ing, was also markedly diminished, as evidenced by reduced Y397
phosphorylation (Figure 4B, lanes 5-8). By contrast, there were mini-
mal changes in phosphorylation of c-Src (at Y416) or p130Cas
(at Y410), despite both being linked to integrin signaling [7].
CD151 and Mammary Gland Development
Many of the same molecules that regulate mammary gland develop-
ment also are involved in breast tumorigenesis [37–39]. Hence, three
pairs of ErbB2-expressing mouse littermates of varying CD151 geno-
types were subjected to whole-mount analyses of mammary glands. As
shown (Figure W3), outgrowth of mammary glands was only a little
altered depending on the presence or absence of CD151 in ErbB2+
mice. Secondary branches appeared to show a small increase in number
accompanied by a reduction in length in CD151-null mice. Similar
Figure 3. Effects of CD151 deletion on primary tumor proliferation
and survival. (A) IHC analyses of sections of primary tumors from
CD151 wild-type (WT) and null (KO) mice: (a and c) staining for Ki-67;
(b and d) for caspase 3. Arrowheads indicate caspase 3–positive
cells. (B) Quantitation of Ki-67 and caspase 3–positive cells (mean±
SEM). Numbers of positive cells per area were calculated for n = 5
mice for each CD151 genotype. Cleaved caspase 3–positive cells
represent 1.5% and 7.5% of total cells in areas counted for WT
and KO mice, respectively. Scale bar, 100 μm.
Figure 4. Loss of CD151 impairs signaling in mouse mammary
tumors. (A) Lysates were prepared from four representative indi-
vidual tumors from CD151 +/+ and −/− mice and blotted with
indicated antibodies. The numbers below ERK1/2 and FAK repre-
sent phosphorylated/total protein ratios from densitometrymeasure-
ments. Activation of ErbB2 and EGFR and their major downstream
effectors was determined by blot analysis with antibodies recogniz-
ing Y1221/1222 of ErbB2, S473 of Akt, and T202/Y204 of ERK. (B)
Changes in integrin-mediated tyrosine phosphorylation cascade.
Phosphorylationof FAKandSrcwasdetectedusing antibodies recog-
nizing Y397 of FAK, Y416 of Src, and p130Cas, respectively. Results
are representative of multiple independent analyses.
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differences were also noted for CD151-null mice in the absence of
ErbB2 oncogene (data not shown).
Recapitulation of In Vivo CD151 Functions Using In Vitro
Cultured Mammary Epithelial Cells
To examine the effects of CD151 in a cell-autonomous system (i.e.,
no possible contributions from tumor microenvironment), we used
MCF-10A/ErbB2 cells in three-dimensional cell culture. In this sys-
tem, differences in size and morphology of colonies reflect tumor-
forming capability of ErbB2-driven carcinoma cells [40–42]. Whereas
control cells formed typical ErbB2-driven disorganized colonies under
three-dimensional culture [40], CD151 ablation by RNAi not only
markedly decreased colony size but also partially restored acini integ-
rity in a 5-day assay (Figure 5A, b and d ).
To reinforce conclusions from Figure 4, we next assessed the ex-
tent to which CD151 synergizes with ErbB2-driven FAK and ERK
pathways to enhance colony size. In a 3-day assay, MCF-10A/ErbB2
cells ablated for CD151 showed only a small and not significant de-
crease in colony size (Figure 5B, DMSO control). However, absence
of CD151 sensitized tumor cell’s response to inhibitors directed
against ErbB2 (lapatinib), FAK (TAE-266), or MEK1/2 (U0126),
causing a 46% to 51% decrease in colony size, compared with con-
trol cells. In contrast, CD151 ablation had little effect on tumor cell
responsiveness to doxorubicin, a conventional chemotherapeutic
agent (Figure 5B).
To recapitulate in vivo effects described in Figure 3B, we then ana-
lyzed CD151 effects on cell survival and proliferation. In a 5-day assay
(Figure 5C , a-c) CD151 ablationmarkedly increased the percentage of
Figure 5. Ablation of CD151 decreases survival of MCF-10A/ErbB2 cells cultured in three dimensions. (A) Images of acinar-like structures
are shown for cells expressing control short hairpin RNA (shRNA) (a, c) or CD151 shRNA (b, d) after 5 days of three-dimensional culture.
Top panel: Representative fields were visualized using a phase-contrast microscope (a, b) and by confocal immunofluorescence imaging
of antibody-stained colonies (c, d). Blue indicates DAPI staining of nuclei; green, antibody staining for smooth muscle actin (SMA). Scale
bar, 50 μm. Right panel: Average colony areas in multiple random fields (mean ± SEM, n = 3). (B) Inhibition of acinar-like colony for-
mation (mean ± SEM, n = 3). Three days after treatment with 0.5 μM lapatinib, 1.0 μM TAE266, 2.0 μM U0126, or 0.5 μM doxorubicin,
colonies were imaged and quantitated. (C) Immunofluorescence analyses were carried out with indicated antibodies or DAPI for nuclear
visualization. Confocal images of stained colonies: cells expressing control shRNA (a, c, e); CD151 shRNA (b, d, f). Staining for Ki-67
(a and b); caspase 3 (c and d); ERK1/2 (e and f). Blue indicates DAPI staining; red, antibody staining. Scale bar, 50 μm. Bottom panel:
Percentages of positively stained cells (mean ± SEM; n = 3). All data are representative of multiple experiments. *P < .05, **P < .01,
***P < .001.
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caspase 3–positive cells, but not Ki-67–positive cells. These changes
were also accompanied by reduced nuclear translocation of ERK
(Figure 5C , e and f ), consistent with reduced ERK activation in vivo
(Figure 4A) and in vitro (Figure 6D).
CD151-Mediated Tumor Progression Correlates with Cell
Motility and Invasion
Given the impact of CD151 removal on spontaneous metastasis
(Figure 2) and its functional link to EGFR [10], we tested whether
CD151 collaborates with EGFR to accelerate early steps of metastasis
involving tumor motility and invasiveness. As shown in Figure 6A,
ablation of CD151 markedly decreased the random motility of
MCF-10A/ErbB2 cells by 30% to 40% on stimulation by EGF, but
not transforming growth factor β (TGF-β). In addition, removal of
CD151 reduced transendothelial migration by 50% (Figure 6B). Fur-
thermore, in the absence of CD151, EGF-stimulated invasion of
MCF-10A/ErbB2 cells through Matrigel was significantly impaired
(Figure 6C ). Next, we tested whether CD151 impacts the signaling
of EGFR or EGFR/ErbB2 heterodimers in MCF-10A/ErbB2 cells
[43]. As anticipated, EGF-stimulated activation of FAK was markedly
diminished in CD151-deficient cells (Figure 6D, lanes 4-6 ), com-
pared with control cells (Figure 6A, lanes 1-3). Activation of ERK
was also reduced, although not quite to the same extent as seen in
mouse tumor samples (Figure 4A).
CD151 Mediates Mammary Tumorigenesis by Impacting
Function and Signaling of Integrin α6β4
Also, we examined the collaboration of CD151with α6β4 integrin, a
major partner of CD151 in mammary epithelial cells [10,12]. By
coimmunoprecipitation, a physical association of CD151 with α6
and β4 integrins was verified in mammary epithelial cells isolated from
ErbB2-transgenic mice (Figure 7A). A crucial role of α6β4 integrin is
also supported by anti-α6β4 antibody (GöH3) inhibition of acinar-like
structures formed by MCF-10A/ErbB2 cells under three-dimensional
culture (Figure 7B). This inhibition is even stronger than seen with
anti-CD151 antibody (1A5) but similar to that elicited by CD151 re-
moval (Figure 5A). To further demonstrate a functional link between
CD151 and α6β4, we performed CD151 mutant rescue experiments.
Reexpression of CD151 (knockdown insensitive) in CD151 knock-
down cells largely restored acinar-like structures (Figure 7C ). In con-
trast, reconstitution with CD151 “EC mutant,” which is defective in
α6β4 association [30], failed to rescue the effect of CD151 knockdown
(Figure 7C ).
Furthermore, we obtained evidence that CD151 regulates α6β4 in-
tegrin phosphorylation at key sites involved in the transition from nor-
mal polarized epithelium to cell migration and invasion [27,28]. As
shown in Figure 8A, tumors derived from CD151-null mice exhib-
ited a marked reduction in β4 integrin phosphorylation at the PKC-
dependent S1424 residue [28] (compare lanes 5-8 with 1-4). A similar
change was observed in β4 S1356 phosphorylation (Figure 8A, lanes 5-8),
Figure 6. Ablation of CD151 inhibits tumor cell motility, invasion, and signaling. (A) To assess random motility, MCF-10A/ErbB2 cells
(with or without CD151 knockdown) were treated with or without 10 ng/ml EGF or 5 ng/ml TGF-β1 for 12 hours. Twenty individual cells
per treatment were tracked, and average distances traveled were calculated (mean ± SEM). (B) Differences in transendothelial migration
(mean ± SEM, n= 6). EGF (10 ng/ml) was added to the bottom chamber as chemoattractant. (C) Invasive capabilities of MCF-10A/ErbB2
cells ± CD151 ablation (mean ± SEM, n = 3) and ±10 ng/ml EGF stimulation. **P < .01, ***P < .001. (D) Activation of FAK and ERK in
response to EGF stimulation. The ratios of phosphorylated versus total proteins were calculated by densitometry analyses.
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which is mediated by PKC and/or ERK1/2 [27]. To confirm these dif-
ferences, we evaluated β4 integrin phosphorylation in MCF-10A/
ErbB2 cells. Again, CD151 ablation caused a reduction in constitutive
β4 integrin phosphorylation at S1424 (Figure 8B). Constitutive β4
S1356 phosphorylation was not diminished, perhaps because it was
already low. On EGF stimulation, β4 integrin phosphorylation at both
S1424 and S1356 sites was reduced when CD151 was absent.
CD151 Gene Expression Correlates with ErbB2-Positive
Breast Cancer Patient Survival
Having seen a strong in vivo effect of CD151 deletion on tumor
appearance and metastasis (Figures 1 and 2), we then investigated
CD151 expression with respect to ErbB2+ breast cancer patient sur-
vival. In a gene expression data set of 132 human primary tumor sam-
ples [44], the concomitant expression of CD151 and ErbB2 genes is
strongly predictive of metastasis-free survival (P = .0082; Figure 9A).
Notably, for patients with a good prognosis, 5-year metastasis-free
survival exceeded 50%, whereas those with a poor prognosis showed
only 10% survival. In another independent breast tumor data set of
295 human samples [45], elevated expression of both CD151 and
ErbB2 genes was again predictive of metastasis-free survival (P = .047;
Figure 9A, right panel ). However, in neither data set was expression of
either CD151 or ErbB2 genes alone associated with metastasis-free
survival (P > .05 in all four cases).
Discussion
With combined approaches of an animal genetic model and a three-
dimensional cell culture model, backed up by human patient survival
data, we demonstrate that tetraspanin CD151 is a critical regulator of
Figure 7. CD151-mediated tumorigenesis involves α6β4 integrin. (A) Mouse stable cell lines were established from primary mouse ErbB2
tumors, labeled with [3H]-palmitate and immunoprecipitated with integrin-specific monoclonal antibodies as described [10,29]. (B) Human
MCF-10A/ErbB2 cells were treated with nonimmune IgG or GöH3 (anti–integrin α6) or 1A5 (anti–CD151) antibodies for 5 days and photo-
graphed. Mean sizes of colonies are indicated. (C) HumanMCF-10A/ErbB2 cells were infected with virus expressing intact human CD151
or EC mutant (defective in α6β4 integrin association) as previously described [30]. The EC mutant was generated by replacing a stretch
of amino acids located in the large extracellular loop of CD151 protein with a corresponding portion from the non–integrin-binding
tetraspanin CD231/A15.
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ErbB2 oncogene–evoked mammary tumorigenesis. Deletion of
CD151 markedly impaired mammary tumor onset, decreased tumor
cell survival, and decreased spontaneous metastasis in ErbB2-transgenic
mice. In three-dimensional cultured cells, CD151 removal again de-
creased mammary epithelial cell survival while also decreasing cell
motility and invasion. Functional consequences of CD151 absence,
in both the mouse model and in three-dimensional cell culture, were
accompanied by substantial decreases in the activation of ERK and
FAK and in the phosphorylation of β4 integrin by PKC and ERK.
Events affected elsewhere in mammary tumor cells by CD151 or LB
integrins (e.g., primary tumor growth rate [10,46], TGF-β signaling
[8], AKT activation [47], and STAT3 activation [42]) were not altered
in our ErbB2-driven mammary cells, either in mouse tumors and/or in
three-dimensional culture. Our novel findings lead to the working
model outlined in Figure 9C .
CD151 Accelerates the Onset of ErbB2-Driven
Mammary Tumors
Our analyses using ErbB2 transgenic mice provide the first demon-
stration that CD151 promotes mammary tumor initiation. Delayed
tumor onset on CD151 deletion (70-100 days) is substantially greater
than the 35-day delay caused by β4 cytoplasmic tail truncation [42].
This longer delay may be at least partly due to CD151 differentially
affecting contributions of multiple integrins (α3β1, α6β1, and α6β4).
We suspect that CD151 acts by modulating LB integrins and other
proteins in tetraspanin-enriched microdomains (TEMs). In this re-
gard, CD151 can affect diffusion mode [15], distribution [10], mem-
brane turnover [48], and glycosylation [49] of LB integrins. Of
particular relevance to tumor onset, CD151 may affect α6 integrins,
which can regulate functions of mammary epithelial stem and progen-
itor cells, both of which are also essential targets of the ErbB2 oncogene
[50,51]. Unexpectedly, mice lacking one or both copies of CD151
showed comparably delayed tumor onset and comparably reduced
tumor metastasis. We speculate that removing one CD151 allele
might impair protumor contributions of α6β4, without much affecting
α3β1. By contrast, on removing both alleles of CD151, additional loss
of protumor α6β4 effects might be counterbalanced by the partial loss
of suppressor effects of α3β1.
CD151 ablation did not much affect ErbB2 and EGFR activation
but did diminish their functions (i.e., responses to EGF, signaling
through FAK and ERK, and conventional PKC [cPKC]– and ERK-
dependent phosphorylations of β4). Notably, FAK has itself been
linked to breast cancer initiation [52,53]. Increased MCF-10A/ErbB2
cell sensitivity to drugs targeting FAK, ErbB2/EGFR, andMEK/ERK
is consistent with these signaling pathways being weakened, as a con-
sequence of CD151 removal.
Analysis of mammary gland architecture revealed a mild defect
in secondary branching, which could influence tumor formation.
However, normal mammary gland development is similarly al-
tered by CD151 deletion even when the ErbB2 transgene is ab-
sent. Further studies are needed to clarify the mechanistic details
underlying CD151 effects on mammary gland development and
ErbB2-driven tumorigenesis.
CD151-Mediated Tumorigenesis Correlates with Survival
rather than Proliferation
The impact of CD151 removal on ErbB2-evoked mammary tumor
onset may be due to diminished survival, rather than diminished cell
proliferation, as seen in both tumor cells and in MCF-10A/ErbB2
model cells. Caspase 3-staining showed ∼6%more cell death occurring
in knockout cells, giving a 1.06-fold advantage to wild-type cells. Dur-
ing the three generations (followed for 3 weeks as in Figure 1B), an
increased growth rate is not that obvious (1.063 = 1.19). However,
during the ∼25 generations needed for single initiated cells to grow
into visible tumors (1.0625 = 4.3), a substantial difference in tumor
size is predicted (about four-fold), which would be consistent with a
delay in appearance of knockout tumors.
Typically, ErbB2 signals through the RAS/RAF/MEK/ERK path-
way to stimulate cell proliferation and migration, whereas it uses the
PI3K/AKT pathway for survival [54]. By contrast, our results show
CD151 supporting ERK activation, not to affect proliferation but
rather to influence survival in an AKT-independent manner. Although
our results are perhaps atypical, at least one other study has linked
ErbB2-dependent activation of ERK1/2 to cell survival [55], and
ERK may promote AKT-independent survival by inactivating the
proapoptotic BAD protein [56]. Our results also show CD151-
dependent activation of FAK in association with cell survival, consistent
with other studies linking FAK to cell survival [57]. Also, CD151 may
use the NF-κB pathway to mediate mammary cell survival. In this re-
gard, forced expression ofNF-κB protein p65/RelA inCD151-deficient
Figure 8. Impact ofCD151 removal onα6β4 integrinphosphorylation.
(A) Tissue extracts prepared from four representative tumors from
CD151 +/+ and −/− mice were blotted with the indicated anti-
bodies to show β4 integrin phosphorylation. (B) Phosphorylation
of β4 integrin in culturedMCF-10A/ErB2 cells was analyzed. Control
shRNA- and CD151 shRNA-expressing cells were stimulated with
EGF (10 ng/ml) for indicated times (minutes) and lysed in RIPA buffer.
Antibodies used to assess phosphorylation of β4 integrin were
described [27,28]. Numbers under blots indicate phosphorylated/
total protein ratios from densitometry analyses. All samples were
run on the same gels and blotted simultaneously with the same
nitrocellulose membranes.
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MCF-10A/ErbB2 cells markedly decreased caspase 3–positive cells in
acinar-like structures (not shown).
CD151 Facilitates Spontaneous Mammary Tumor Metastasis
In various tumor cell injection models, CD151 sometimes sup-
ported in vitro cell invasion or experimental metastasis (Introduction),
but its role in spontaneous metastasis was not addressed. Here we show
that CD151 deletion caused a significant reduction in spontaneous
metastases in MMTV-ErbB2 mice. In both primary and metastatic
samples, CD151 loss yielded a transition from irregular invasive-like
borders to smoother sheet-like epithelial morphologies, with a marked
reduction in recruitment of stromal-like cells. These changes suggest
altered tumor cell interactions with local microenvironment—a topic
that requires further study.
CD151 ablation from ErbB2+ cells caused marked reductions in tu-
mor cell invasion, random migration, and transendothelial migration,
consistent with decreased metastatic capability. CD151 may drive tu-
mor metastasis largely through EGFR-, FAK-, and PKC-mediated
pathways. A close CD151 connection to FAK activation (in both
tumors and in MCF-10A/ErbB2 cells) is consistent with CD151
and FAK effects on breast cancer cell sensitivity to ErbB2 antagonists
[12]. cPKC isoforms (i.e., PKCα) are crucial for α6β4 and ErbB recep-
tor function during cell migration and metastasis [28,58]. Also, cPKC
(together with ERK) supports phosphorylation of β4 at S1356 and
S1424 [27,28]. Reduced phosphorylation at these sites in CD151-
deficient cells is consistent not only with dysregulated cPKC function
but also with diminished cell migration and invasion [27]. Diminished
FAK activation was not accompanied by diminished Src and p130Cas
activation, thus indicating a more restricted signaling phenotype in
our ErbB2-driven mammary tumors, compared with CD151-ablated
lung adenocarcinoma cells [59]. As suggested [10], Lck may possibly
replace Src in the FAK signaling pathway.
CD151 can associate and functionally collaborate not only with
α6β4 but also with α3β1, as seen in ErbB2
+ breast cancer cell lines [12].
Consistent with this, the absence of CD151 affected cell adhesion to
laminin 5 (ligand for α3β1 and α6β4). In other breast cancer cell lines
(not expressing ErbB2), integrin α3β1 can contribute to in vitro invasion
and in vivo experimental metastasis (Figure W4) [60,61]. However, we
suspect that, for ErbB2+ breast cancer, CD151 is mostly supporting
functions of α6β4 and perhaps also of α6β1. In this regard, MCF-10A/
ErbB2 cell colony formation largely involved CD151 collaboration with
α6 integrins (e.g., Figure 7), whereas inhibition of α3β1 minimally
affected the size of colonies formed by three-dimensional culturedmam-
mary cells (not shown). Nonetheless, we have not ruled out a role for
Figure 9. Correlation of CD151 gene expression with metastasis-free survival of breast cancer patients. (A) Kaplan-Meier metastasis-free
survival curves were constructed from data sets containing CD151 and ErbB2 gene expression information from 132 human primary
tumor samples [44]. (B) Similar curves are constructed from data sets containing CD151 and ErbB2 information from 295 human sam-
ples [45]. Statistical significance (in A and B) is evaluated using the log-rank test. (C) A working model is shown for CD151 function
during ErbB2-evoked mammary tumor onset and metastasis.
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α3β1 in CD151-dependent regulation of ErbB2-driven tumor onset and
metastasis in vivo.
Where Is CD151 Functioning?
Results from our three-dimensional cell culture analyses of human
mammary epithelial cells largely recapitulate the in vivo impact of
CD151 removal, confirming a direct role of CD151 in ErbB2-evoked
mammary tumorigenesis and metastasis. Nonetheless, CD151 could
also affect ErbB2+ tumor onset and metastasis indirectly through other
cells and tissues, such as endothelial cells [20], kidneys [23,24,62], or
immune cells [63]. Although tumor angiogenesis did not seem to be
diminished at primary tumor sites, we cannot rule out CD151 contrib-
uting to metastasis by supporting lung endothelial cell function [64].
Although CD151 deletion can seriously impact kidney function in
FVBmice [24], we avoided this problem by backcrossing CD151-null
mice into FVB for only three generations. Indeed, our results strongly
suggest that the effects of CD151 on tumor onset and metastasis
are independent of kidney pathology. With respect to potential im-
mune cell contributions, CD151 deletion from tumor-bearing mice
so far does not affect immune cell subset sizes, activation, trafficking,
or infiltration into tumors [64].
CD151 as a Promising Therapeutic Target
Our results consistently demonstrate that CD151 supports mam-
mary tumorigenesis, particularly with respect to tumor onset, metas-
tasis, and survival, in association with key signaling pathways involving
FAK, ERK, and integrin β4 phosphorylation. Given the strong corre-
lation between CD151 expression and poor metastasis-free survival of
ErbB2+ breast cancer patients (Figure 9, A and B) and the role of
CD151 in basal-like breast tumor malignancy [10,11,46], we predict
that targeting CD151 could serve as another treatment option for
breast cancer patients with ER− tumors. It remains to be seen whether
targeting of CD151 would have adverse effects in the skin and kidney
[23,24,62] or would have minimal effects on the skin or kidney or
any other normal cells and tissues in vivo [65].
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Figure W1. Effect of CD151 on mammary tumor metastasis. (A) In-
cidence of spontaneous pulmonary metastatic lesions in ErbB2
transgenic mice is indicated. (B) Effects of CD151 deletion on sizes
of metastatic lesions (and mean size values) are shown.
Figure W2. Hematoxylin and eosin staining of kidney sections frommice used in Figure 1A. At the end of in vivo tumormonitoring, kidneys
were removed from (A)wild-typemice (n=6), (B) CD151+/−mice (n=4), (C-E) CD151 KOmice (n=11): C,mild; D, intermediate; E, severe.
Figure W4. Absence of CD151 affects tumor cell adhesion. Cell
lines were derived from tumors developed in CD151 WT and KO
mice and then analyzed for adhesion to laminin 5–coated plastic
surfaces at different doses.
Figure W3. Effect of CD151 removal on outgrowth of mammary
glands in ErbB2-transgenic mice. Representative whole-mounted
mammary glands from 6- to 8-week-old ErbB2-positive mice
(n = 3). Results are representative of three mice per group.
